🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesEchocardiographic changes on GLP-1 — what worked for you?

Echocardiographic changes on GLP-1 — what worked for you?

oliver_london Sun, Oct 12, 2025 at 3:50 PM 8 replies 1,217 viewsPage 1 of 2
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
oliver_london
Member
312
1,345
Aug 2024
London, UK
Oct 12, 2025 at 3:50 PM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

What I am trying to establish is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

I have searched first, so if this is covered somewhere point me at it and I will read it.

36 14Admin, Dr.Martinez, mike_mod and 33 others
Reply Quote Save Share Report
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Oct 12, 2025 at 4:49 PM#2
oliver_london said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Senior perspective on cardiovascular risk: I'm 66 years old and started this journey skeptically. My cardiologist recommended it after years of failed interventions.

14 months later: down 39 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

37 15AmyNC_wife, SkepticalSean, Dr.CardioMD and 34 others
Reply Quote Save Share Report
sarah.morrison
VIP Member
3,212
14,567
Jan 2024
California
Online
Oct 12, 2025 at 5:48 PM#3
RetaRick_CA said:
Senior perspective on cardiovascular risk: I'm 66 years old and started this journey skeptically.

I'm 67 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

17 months later: down 64 lbs, off atorvastatin, A1C from 8.8% to 5.3%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

Last edited: Oct 12, 2025 at 6:48 PM
38 16tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 35 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
hyun_seoul
Member
345
1,456
Jul 2024
Seoul, KR
Oct 12, 2025 at 6:47 PM#4
oliver_london said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Can confirm. Same sequence, different timescale.

Last edited: Oct 12, 2025 at 10:47 PM
39 17BariatricNurseD, MASHdoc_SA, GenomicsKate and 36 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Oct 13, 2025 at 12:21 AM#5

Clinical perspective, offered as context rather than as advice.

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

  • NT-proBNP: 52 pg/mL (normal, cardiac function preserved)
  • Lp(a): 32 nmol/L (genetic, unchanged — expected)
  • ApoB: dropped from 137 to 92 mg/dL (excellent response)
  • Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

Last edited: Oct 13, 2025 at 1:21 AM
40 18FranDenver, Dr.BariatricHTX, LindaRN_retired and 37 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register